Table 1. Demographic, epidemiological, and clinical characteristics of 586 COVID-19 hospitalized adults ≥65 years old.
GRF: Glomerular Filtration rate. HIV: human immunodeficiency virus. SD: standard deviation
*2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. **European AIDS Clinical Society Guidelines Version 11.0, October 2021.
| Demographic | 65 to 79 years old, n (%) | ≥80 years old, n (%) |
| Total | 193 (33%) | 393 (67%) |
| Female | 97 (50.30%) | 224 (57%) |
| Male | 96 (49.70%) | 169 (43%) |
| Median age (years ±(SD)) | 73.6 ±(4.02) years | 87.50 (±5.03) years |
| Modified Rankin Score | ||
| 0 | 46 (23.8 %) | 22 (5.6%) |
| 1 | 56 (29.0%) | 53 (13.5%) |
| 2 | 11 (5.7%) | 34 (8.6%) |
| 3 | 26 (13.5%) | 56 (14.2%) |
| 4 | 24 (12.4%) | 94 (24%) |
| 5 | 30 (15.5%) | 134 (34.1%) |
| Deaths | 53 (28%) | 182 (46.3%) |
| Comorbidities | ||
| Chronic kidney disease (GRF<60mL/min/1.73m2) | 19 (9.8%) | 93 (23.6%) |
| Chronic liver disease* | 6 (3.1%) | 3 (0.8%) |
| Diabetes mellitus (HbA1>6.5%) | 76 (39.4 %) | 119 (30%) |
| Heart failure* | 30 (15.5%) | 127(32.6%) |
| HIV** | 2 (1.0%) | 1 (0.3%) |
| Hypertension (TA > 140/90mmHg) | 139 (72%) | 304 (77.4%) |
| Immunosuppressant drugs (steroids, anti-TNF alpha, biological, chemotherapy) | 4 (2.1%) | 8 (2%) |
| Lung Disease (asthma, COPD, pulmonary fibrosis, lung cancer) | 44 (22.8%) | 79 (20.1%) |
| Neoplasm | 24 (12.4%) | 47 (12%) |
| Obesity (IMC>25kg/m2) | 43 (22.3%) | 70 (17.8%) |
| Smoker | 13 (6.8%) | 7 (1.8%) |